‘Challenging’ Times For Sandoz As COVID Bites

Sales And Core Operating Profit See Double-Digit Declines Despite Biopharma Growth

Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.

COVID coronavirus impact graph recovery
Sandoz expects its business to stabilize as pandemic pressures ease • Source: Alamy

Sandoz has experienced a tough start to 2021 as pandemic-related pressures combined to drive down sales and profit in what management described as a “challenging” first quarter.

While parent company Novartis offered a relatively limited breakdown of Sandoz’ performance as it published first-quarter results today, it did...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business